Last quarter (Q3 2024), Vaxil Bio's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Vaxil Bio's net income was $-49.00K. See Vaxil Bio’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ 138.00K	$ 259.00K	$ 584.00K	$ 986.00K	$ 1.35M	$ 1.14M
Operating Income	$ -138.00K	$ -259.00K	$ -584.00K	$ -986.00K	$ -1.35M	$ -1.14M
Net Non Operating Interest Income Expense	$ 8.00K	$ ―	$ ―	$ ―	$ 11.00K	$ 11.00K
Other Income Expense	$ ―	$ -5.00K	$ ―	$ ―	$ ―	$ ―
Pretax Income	$ -130.00K	$ -254.00K	$ -584.00K	$ -986.00K	$ -1.36M	$ -1.15M
Tax Provision	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -130.00K	$ -254.00K	$ -584.00K	$ -986.00K	$ -1.36M	$ -1.15M
Basic EPS	$ ―	$ ―	$ -0.01	$ -0.01	$ -0.01	$ -0.01
Diluted EPS	$ ―	$ ―	$ -0.01	$ -0.01	$ -0.01	$ -0.01
Basic Average Shares	$ 547.92M	$ 136.98M	$ 136.98M	$ 136.10M	$ 101.74M	$ 88.93M
Diluted Average Shares	$ 547.92M	$ 136.98M	$ 136.98M	$ 136.10M	$ 101.74M	$ 88.93M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 81.00K	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ -130.00K	$ -254.00K	$ -584.00K	$ -986.00K	$ -1.36M	$ -1.15M
Normalized Income	$ -135.33K	$ -191.69K	$ -429.24K	$ -724.71K	$ -998.13K	$ -848.19K
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -130.00K	$ -254.00K	$ -584.00K	$ -986.00K	$ -1.35M	$ -1.14M
EBITDA	$ -130.00K	$ -254.00K	$ -582.00K	$ -961.00K	$ -1.29M	$ -1.04M

Currency in USD

Vaxil Bio Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing